Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dived deep into the world of myeloproliferative neoplasms (MPNs), focusing specifically on polycythemia vera (PV) and essential thrombocythemia (ET). They are joined by Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, who shared his expertise on the latest treatment paradigms and risk stratification strategies for these conditions. Key topics discussed included: • The importance of ruling out secondary causes of erythrocytosis in PV patients. • The role of JAK2 mutation testing and EPO levels in diagnosis of PV. • Treatment options for PV, including phlebotomy, hydroxyurea, and interferon, as well as the emerging role of ruxolitinib. • Risk stratification in ET and the significance of driver mutations like JAK2, CALR, and MPL. • The management of acquired von Willebrand disease in patients with high platelet counts. • Insights from Dr. Kuykendall's recent ASCO plenary presentation on the VERIFY Study and the potential of resveratide in PV treatment. Join us for an informative discussion that highlights the evolving landscape of MPN management and the importance of individualized treatment plans. Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ Don't forget to check out our other hematology episodes for more insights into challenging cases and treatment algorithms! #MPNtreatment #PolycythemiaVera #JAK2mutation #Ruxolitinib #OncologyBrothers